Research programme: alpha-2B adrenoceptor antagonists - Juvantia Pharma
Alternative Names: Alpha-2B adrenoceptor antagonists research programme - Juvantia PharmaLatest Information Update: 18 Feb 2009
At a glance
- Originator Juvantia Pharma
- Class
- Mechanism of Action Alpha 2b adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 20 Jul 2005 This programme is still in active development - (BIO-2005)
- 31 Jan 2001 New profile
- 31 Jan 2001 Preclinical development for Vascular disorders in Finland (Unknown route)